141 related articles for article (PubMed ID: 25170659)
1. Investigation of factors affecting in vitro doxorubicin release from PEGylated liposomal doxorubicin for the development of in vitro release testing conditions.
Shibata H; Izutsu K; Yomota C; Okuda H; Goda Y
Drug Dev Ind Pharm; 2015; 41(8):1376-86. PubMed ID: 25170659
[TBL] [Abstract][Full Text] [Related]
2. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
3. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
4. Development of an in vitro drug release assay of PEGylated liposome using bovine serum albumin and high temperature.
Hioki A; Wakasugi A; Kawano K; Hattori Y; Maitani Y
Biol Pharm Bull; 2010; 33(9):1466-70. PubMed ID: 20823558
[TBL] [Abstract][Full Text] [Related]
5. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
7. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats.
Yokoe J; Sakuragi S; Yamamoto K; Teragaki T; Ogawara K; Higaki K; Katayama N; Kai T; Sato M; Kimura T
Int J Pharm; 2008 Apr; 353(1-2):28-34. PubMed ID: 18082345
[TBL] [Abstract][Full Text] [Related]
8. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic model and analysis of doxorubicin release from liposomal formulations.
Fugit KD; Xiang TX; Choi du H; Kangarlou S; Csuhai E; Bummer PM; Anderson BD
J Control Release; 2015 Nov; 217():82-91. PubMed ID: 26310713
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination.
Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN
J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563
[TBL] [Abstract][Full Text] [Related]
12. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin.
Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL
Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968
[TBL] [Abstract][Full Text] [Related]
13. Ammonium ion level in serum affects doxorubicin release from liposomes.
Shibata H; Saito H; Yomota C; Kawanishi T
Pharmazie; 2010 Apr; 65(4):251-3. PubMed ID: 20432619
[TBL] [Abstract][Full Text] [Related]
14. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
[TBL] [Abstract][Full Text] [Related]
16. Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs.
Schilt Y; Berman T; Wei X; Nativ-Roth E; Barenholz Y; Raviv U
Biochim Biophys Acta Gen Subj; 2021 May; 1865(5):129849. PubMed ID: 33460771
[TBL] [Abstract][Full Text] [Related]
17. Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models.
Burade V; Bhowmick S; Maiti K; Zalawadia R; Ruan H; Thennati R
BMC Cancer; 2017 Jun; 17(1):405. PubMed ID: 28587612
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin.
Jiang W; Lionberger R; Yu LX
Bioanalysis; 2011 Feb; 3(3):333-44. PubMed ID: 21320053
[TBL] [Abstract][Full Text] [Related]
19. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques.
Mayer LD; St-Onge G
Anal Biochem; 1995 Dec; 232(2):149-57. PubMed ID: 8747469
[TBL] [Abstract][Full Text] [Related]
20. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
